US2012165566A1PendingUtilityA1
Processes for intermediates for macrocyclic compounds
Est. expiryJun 18, 2023(expired)· nominal 20-yr term from priority
A61P 3/04A61P 43/00A61P 25/00A61P 3/10A61P 1/04C07D 413/06A61K 38/2214A61P 1/00C07K 5/0812C07D 273/00A61P 1/18C07K 5/0827C07C 213/08C07C 67/343C07C 41/18C07D 498/04A61P 1/12A61K 38/12C07K 5/0821
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
Claims
exact text as granted — not AI-modified1 - 29 . (canceled)
30 . A compound of formula (II):
wherein R 1 is C 1 -C 4 alkyl; X is halogen or triflate; and PG 3 is hydrogen or an ester protecting group.
31 . The compound of claim 30 , wherein X is iodine.
32 . The compound of claim 30 , wherein R 1 is methyl.
33 . The compound of claim 30 , wherein PG 3 is an alkyl group or an alkyl group substituted with an aryl group.
34 . The compound of claim 30 represented by the following structures:
wherein PG 3 is hydrogen or an ester protecting group.
35 - 46 . (canceled)
47 . The compound of claim 34 , wherein PG 3 is hydrogen.
48 . The compound of claim 34 , wherein PG 3 is an alkyl group or an alkyl group substituted with an aryl group.
49 . The compound of claim 48 , wherein PG 3 is methyl.
50 . The compound of claim 48 , wherein PG 3 is ethyl.
51 . The compound of claim 48 , wherein PG 3 is benzyl.
52 . A process of using a compound of claim 30 to make a compound of formula (I);
wherein R 1 is C 1 -C 4 alkyl.
53 . A process of using a compound of claim 30 to make a compound of formula (G);
wherein R 1 is C 1 -C 4 alkyl and PG 1 is an amine protecting group.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.